<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>CONTEXT: Vasoconstricting beta-blocker use is associated with a reduction in <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi>, higher <z:chebi fb="0" ids="17855">triglyceride</z:chebi>, total cholesterol and <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> levels, whereas <z:chebi fb="0" ids="3441">carvedilol</z:chebi>, a vasodilating beta-blocker, has not been associated with these effects </plain></SENT>
<SENT sid="1" pm="."><plain>OBJECTIVE: To compare in a randomized, double-blind study, the effects of the beta 1-blocker <z:chebi fb="0" ids="6904">metoprolol</z:chebi> <z:chebi fb="1" ids="15193,50562">tartrate</z:chebi> with the combined alpha 1, beta-blocker <z:chebi fb="0" ids="3441">carvedilol</z:chebi> on serum <z:chebi fb="23" ids="18059">lipid</z:chebi> concentrations </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: A prospective randomized, double-blind, parallel-group trial compared the effects of <z:chebi fb="0" ids="3441">carvedilol</z:chebi> and <z:chebi fb="0" ids="6904">metoprolol</z:chebi> on total cholesterol, <z:chebi fb="4" ids="17855">triglycerides</z:chebi>, calculated <z:chebi fb="15" ids="39026">LDL</z:chebi>, <z:chebi fb="17" ids="39025">HDL</z:chebi> and non-<z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> levels at baseline and after 5 months of therapy as a secondary objective in the Glycemic Effects in <z:hpo ids='HP_0000819'>Diabetes Mellitus</z:hpo>: <z:chebi fb="0" ids="3441">Carvedilol</z:chebi>-<z:chebi fb="0" ids="6904">Metoprolol</z:chebi> Comparison in Hypertensive (GEMINI) study </plain></SENT>
<SENT sid="3" pm="."><plain>In this study, 1235 participants with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0000822'>hypertension</z:hpo> who were receiving renin-angiotensin system blockers were randomized either to <z:chebi fb="0" ids="3441">carvedilol</z:chebi>, receiving 6.25-25 mg twice daily, or to <z:chebi fb="0" ids="6904">metoprolol</z:chebi> <z:chebi fb="1" ids="15193,50562">tartrate</z:chebi>, receiving 50-200 mg twice daily </plain></SENT>
<SENT sid="4" pm="."><plain>If needed, hydrochlorothiazide and a <z:chebi fb="0" ids="50075">dihydropyridine</z:chebi> <z:chebi fb="1" ids="38215">calcium channel blocker</z:chebi> were added to achieve blood pressure goals </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: In the <z:chebi fb="0" ids="6904">metoprolol</z:chebi> <z:chebi fb="1" ids="15193,50562">tartrate</z:chebi> group, <z:chebi fb="4" ids="17855">triglycerides</z:chebi> and non-<z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> increased and both the <z:chebi fb="15" ids="39026">LDL</z:chebi> and the <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> levels decreased </plain></SENT>
<SENT sid="6" pm="."><plain>In the <z:chebi fb="0" ids="3441">carvedilol</z:chebi> group, total <z:chebi fb="15" ids="39026">LDL</z:chebi> and <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> decreased, non-<z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> was unchanged and <z:chebi fb="4" ids="17855">triglycerides</z:chebi> increased </plain></SENT>
<SENT sid="7" pm="."><plain>Comparing the <z:chebi fb="0" ids="3441">carvedilol</z:chebi> and <z:chebi fb="0" ids="6904">metoprolol</z:chebi> <z:chebi fb="1" ids="15193,50562">tartrate</z:chebi> groups, there was no statistically significant difference in <z:chebi fb="15" ids="39026">LDL</z:chebi> and <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> levels, but there was a significantly greater decreases with <z:chebi fb="0" ids="3441">carvedilol</z:chebi> in total cholesterol [-2.9%, 95% confidence interval (CI) -4.60 to -1.15, p &lt; 0.001], <z:chebi fb="4" ids="17855">triglycerides</z:chebi> (-9.8%, 95% CI -13.7, -5.75%, p &lt; 0.001) and non-<z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> (-4.03%, 95% CI -6.3 to -1.8, p &lt; 0.0006) </plain></SENT>
<SENT sid="8" pm="."><plain>At the end of the study, significantly more participants in the <z:chebi fb="0" ids="6904">metoprolol</z:chebi> <z:chebi fb="1" ids="15193,50562">tartrate</z:chebi> group had had initiation of <z:chebi fb="0" ids="35664">statin</z:chebi> therapy or the <z:chebi fb="0" ids="35664">statin</z:chebi> dose increased than those in the <z:chebi fb="0" ids="3441">carvedilol</z:chebi> group (11 vs. 32%, p = 0.04) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: In patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> currently receiving a renin-angiotensin blocker, compared with <z:chebi fb="0" ids="6904">metoprolol</z:chebi> <z:chebi fb="1" ids="15193,50562">tartrate</z:chebi>, the addition of <z:chebi fb="0" ids="3441">carvedilol</z:chebi> for blood pressure control resulted in a significant decrease in <z:chebi fb="0" ids="17855">triglyceride</z:chebi>, total cholesterol and non-<z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> levels </plain></SENT>
<SENT sid="10" pm="."><plain>The use of <z:chebi fb="0" ids="6904">metoprolol</z:chebi> resulted in a significantly greater rate of initiation of <z:chebi fb="0" ids="35664">statin</z:chebi> therapy or an increase in the dose of existing <z:chebi fb="0" ids="35664">statin</z:chebi> therapy when compared with <z:chebi fb="0" ids="3441">carvedilol</z:chebi> utilization </plain></SENT>
</text></document>